Taisho Pharmaceutical Holdings Co., Ltd. (TAISF) Research

Taisho Pharmaceutical Holdings Co., Ltd., headquartered in Tokyo, Japan, is a long-established global pharmaceutical company, founded in 1912. The company and its subsidiaries are comprehensively involved in the research, development, manufacturing, marketing, and distribution of both over-the-counter (OTC) consumer health products and prescription pharmaceuticals, serving markets within Japan and around the world. Its operations are distinctly organized into two primary divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Operation Group concentrates on consumer health products. This segment provides a diverse array of OTC drugs, quasi-drugs, nutritional items, and general health and hygiene supplies. Key brands include the Lipovitan range of energy drinks, Pabron for cold and sinus relief, RiUP hair regrowth treatments, Taisho Kampo for digestive health, Colac laxatives, Naron and other products for pain and fever relief (antipyretic analgesics), Preser hemorrhoid treatments, and internationally recognized brands such as Hapacol, Efferalgan, Dafalgan, and Tempra (also antipyretic analgesics), Counterpain topical anti-inflammatory analgesics, Vitacilina for dermatological care, and VICKS cough suppressants and medicated drops. Beyond its pharmaceutical offerings, this division also has ventures in real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Operation Group focuses on ethical drugs. Its portfolio features medications like Edirol (an active vitamin D3 agent for osteoporosis), Clarith (a macrolide antibiotic), Palux (a peripheral vasodilator), Bonviva (a bisphosphonate osteoporosis agent), Lusefi (for type 2 diabetes mellitus), and LOQOA (a transdermal anti-inflammatory analgesic). This segment maintains an active research pipeline, with numerous products currently under development, primarily targeting therapeutic areas such as central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials essential for pharmaceuticals and quasi-drugs, alongside offering a range of health foods and skincare items.

Open Taisho Pharmaceutical Holdings Co., Ltd. (TAISF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.